Prognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) in patients with localized upper tract urothelial carcinoma

Oncotarget. 2017 May 30;8(22):36761-36771. doi: 10.18632/oncotarget.13611.

Abstract

Purpose: Hemostatic factors is thought to have a potentially significant role in progression and metastasis of malignant tumors. We investigated the prognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (PLR) in localized upper tract urothelial carcinoma (UTUC).

Materials and methods: A total of 481 patients who underwent radical nephroureterectomy for localized UTUC (pTa-4N0M0) were identified between January 2002 and June 2013. Patients were assigned a F-PLR score of 0, 1, or 2 based upon the presence of elevated plasma fibrinogen level, an elevated PLR, or both. The association between F-PLR score and clinicopathological variables was analysed.

Results: The optimal cut-off value of plasma fibrinogen and PLR for overall survival stratification was determined to be 4.22 and 241.2. Kaplan-Meier analysis revealed significant differences in cancer specific survival (CSS) and overall survival (OS) among patients with F-PLR scores of 0, 1 and 2. Multivariate analysis identified higher F-PLR score as an independent risk factor for CSS (P < 0.001) and OS (P < 0.001). The estimated c-index of the multivariate model for CSS and OS increased from 0.772 and 0.756 to 0.799 and 0.784 when F-PLR score added, which was higher than fibrinogen level, PLR or neutrophil-to-lymphocyte ratio added.

Conclusions: Preoperative F-PLR score is a negative independent prognostic factor for survival outcomes in patients with localized upper tract urothelial carcinoma. Preoperative F-PLR score may become a useful biomarker, particularly because of its low associated cost and easy accessibility.

Keywords: fibrinogen; platelet-to-lymphocyte ratio; prognosis; upper tract; urothelial carcinoma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers
  • Combined Modality Therapy
  • Comorbidity
  • Female
  • Fibrinogen / metabolism*
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Lymphocyte Count*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Platelet Count*
  • Preoperative Period
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Ureteral Neoplasms / blood*
  • Ureteral Neoplasms / diagnosis
  • Ureteral Neoplasms / mortality*
  • Ureteral Neoplasms / therapy

Substances

  • Biomarkers
  • Fibrinogen